“We see many patients with spinal cord injuries, which makes us a great candidate for the INSPIRE study. There is a shortage of treatments for spinal cord injury and we look forward to being a part of this promising study,” said Martina Stippler, M.D., Director of Neurotrauma in the Division of Neurosurgery at BIDMC and Principal Investigator at the study site.
Mark Perrin, InVivo’s CEO and Chairman, said, “We are pleased to welcome Dr. Stippler and the interdisciplinary team at Beth Israel Medical Center to the INSPIRE study. We look forward to working with BIDMC, our first Boston-area site.”
Nice, nicer, nicest
8.45 a.m OC59 - 9-Months and 12-Months Safety and Exploratory Efficacy Data of ANAVEX 2-73 in a Phase 2a Study
in Mild-to-Moderate Alzheimer’s Disease Patients
Stephen Macfarlane, MD1, Marco Cecchi, PhD2, Paul Maruff, PhD3 , Kristina M Kapiak4, Christopher U Missling, PhD4
(1) Caulfield Hospital, Melbourne, Australia, (2) Neuronetrix, Louisville, KY, USA, (3) Cogstate Ltd., Melbourne, Australia, (4) Anavex Life Sciences Corp., New York, NY,
"CONCLUSIONS: AV1066 showed robust, dose-dependent efficacy in 2 different animal models of pain, the CCI model of neuropathic pain and the TNBS model of visceral pain, suggesting therapeutic potential in 2 distinct and poorly served patient populations. Further studies will (1) confirm the safety profile suggested in the current studies, (2) explore synergy in combination with subthreshold doses of marketed analgesics, and (3) expand the product profile with the use of additional animal models of chronic pain." from I hub poster..it's a type of news
Been waiting a long time to see some REALLY good news like FDA news, or MJFF news, or Rett news, or PD news, or AD news. We are so due for real news. Lets all have a great Tuesday, we are due.
Agree. Even the use of Biogen's name by AVXL in publication would have been heavily scrutinized before any such release. That would have involved careful review by all relevant staff with a close review of risks and consequences. There is a lot more to this than a simple use of protocols.
Certainly BIogen would have approved the release from AVXL ahead of time. This is significant action by a legitimate BP player and a demonstration of a major potential science win-win. Not a decision taken lightly by AVXL, kind of a bet the farm move in a way. Been around here a long time w/good/not good days, this a different kind of good day. These are serious people doing serious work with massive stakes and mutual success as a positive motivation. As the Irish say, "all the best"
Just wait, some POS will write another hate piece and then MF will jump on and BP will pay up...we need an advocate in a powerful place .
Is NVIV traveling in a different time-space continuum along with other bio's I hold like AVXL, RGIN, MSTX to name a few. I think they each have potential but have not moved much in recent months. Is it a Bio thing?
Isn't that basically what BP has been doing for 30 years(kicking the can), with a few notable exceptions.